Literature DB >> 4039168

Cardiovascular effects of the positive inotropic agents pimobendan and sulmazole in vivo.

J C von Meel.   

Abstract

The effects of the cardiotonics sulmazole (AR-L 115 BS, Vardax) and pimobendan (UD-CG 115 BS) on cardiac contractility, heart rate and diastolic blood pressure were investigated in vivo in pithed guinea pigs, anaesthesized cats and conscious dogs. UD-CG 115 BS proved to be about 5-6 times more active than AR-L 115 BS as a positive inotropic agent in pithed guinea pigs and anaesthetized cats. The hypotensive effects of AR-L 115 BS and UD-CG 115 BS were comparable in pithed guinea pigs whereas UD-CG 115 BS showed stronger hypotensive effects than AR-L 115 BS in anaesthetized cats. A dose of 5 mg/kg of AR-L 115 BS evoked positive inotropic effects during 4-5 h after oral administration to conscious dogs. UD-CG 115 BS (1 mg/kg p.o.) induced a strong increase in LV-dp/dtmax in conscious dogs. These positive inotropic effects lasted for more than 8 h with negligible effects on diastolic blood pressure and heart rate.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4039168

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  8 in total

1.  Haemodynamic profile of an inhibitor of phosphodiesterase III, adibendan (BM 14.478): comparison with nitroprusside and dobutamine in conscious dogs.

Authors:  A Dorszewski; B Müller-Beckmann; L Kling; G Sponer
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

2.  Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.

Authors:  H von der Leyen; U Mende; W Meyer; J Neumann; M Nose; W Schmitz; H Scholz; J Starbatty; B Stein; H Wenzlaff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

3.  Influence of the calcium-sensitizer UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Comparison with nitroprusside.

Authors:  G Hasenfuss; C Holubarsch; H W Heiss; B Rattert; H Just
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

4.  Plasma and red blood cell pharmacokinetics of pimobendan enantiomers in healthy Chinese.

Authors:  K M Chu; S M Shieh; O Y Hu
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 5.  Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.

Authors:  A Fitton; R N Brogden
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

6.  Systemic haemodynamic actions of pimobendan (UD-CG 115 BS) and its O-demethylmetabolite UD-CG 212 Cl in the conscious pig.

Authors:  D J Duncker; J M Hartog; L Levinsky; P D Verdouw
Journal:  Br J Pharmacol       Date:  1987-07       Impact factor: 8.739

7.  Cardiac and coronary vasodilator profile of pimobendan, a new cardiotonic drug, revealed by use of isolated, blood-perfused dog heart preparations.

Authors:  J Imagawa; K Satoh; N Taira
Journal:  Heart Vessels       Date:  1987       Impact factor: 2.037

8.  Effects of pimobendan on left atrial transport function in cats.

Authors:  Samantha L Kochie; Karsten E Schober; Jaylyn Rhinehart; Randolph L Winter; John D Bonagura; Annie Showers; Vedat Yildez
Journal:  J Vet Intern Med       Date:  2020-11-26       Impact factor: 3.175

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.